FDA grants pri­or­i­ty re­view for Dupix­ent in COPD, sets June ap­proval de­ci­sion dead­line

Sanofi and Re­gen­eron’s megablock­buster Dupix­ent just got one step clos­er to a land­mark ap­proval.

The FDA has grant­ed a pri­or­i­ty re­view with a tar­get dead­line of June 27 for an ap­proval de­ci­sion on Dupix­ent for a sub­set of chron­ic ob­struc­tive pul­monary dis­ease pa­tients, the drug­mak­ers said Fri­day. If ap­proved, it would be the first bi­o­log­ic to treat that form of COPD, a space where oth­er phar­ma ef­forts have stum­bled, like As­traZeneca’s Fasen­ra and GSK’s Nu­cala.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER